Funding Details
- Awarder
- StartEngine
- Date Award
- June 13, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Premoney Valuation
-
$1,000,000
- Valuation
-
$196,270,000
Company Info
- Founding Year
- Not provided in the memo
- Traction
- None
- Organizations Involved
- MD Anderson Cancer Center, University of Pennsylvania Medical Center, Yale Medical Center, Harvard University Medical School, Cleveland Clinic
- Founders
- Lynnet Koh, Michael Lemaire, Alan Lewis
- Company Description
- TargaZyme is pioneering the next frontier of cancer medicine with the development of therapeutics that harnesses the power of a patient’s own immune system without the toxic chemotherapies, radiation, radical surgery or other toxic cancer drugs that make up today’s standard of care. TargaZyme is currently pre-revenue and in the R&D stage with our two breakthrough approaches: TZ101, a Phase-3 ready product, and TZ102, which is currently being prepared for clinical or human-patient trials.
- Market
- Cancer Medicine
- Location
-
Carlsbad,
CA,
US
- Coinvestors
- None
Links